



13 September 2021

ASX ANNOUNCEMENT

HFSA Abstracts Demonstrate the Utility of SOZO for HF Patients

ImpediMed Limited (ASX:IPD) today announced two abstracts are being presented in the poster session of the prestigious Heart Failure Society of America (HFSA) Annual Scientific Meeting September 10 – 13, 2021. The abstracts were from studies conducted at Scripps Memorial Hospital campuses and were accepted in the Clinical Care category.

The abstracts were as follows:

Time to decongestion following heart failure hospitalisation as measured by extracellular fluid nadir using bioimpedance spectroscopy (BIS).

This was a multi-centre observational study evaluating volume status of heart failure patients recently discharged from hospital and undergoing a diuretic regimen, with reducing extracellular fluid (ECF) being the main objective of the therapy. The study undertook daily SOZO[®] BIS measurements to track fluid status and compared them to corresponding weight measurements. It took an average of 16.9 days for patients to reach their lowest extracellular fluid volume following a heart failure-related hospital stay. During this time, patients experienced more than a two-fold ECF loss as compared to weight loss on a percentage basis, demonstrating the sensitivity of BIS as diuretic decongestion reduces ECF.

The abstract concluded: Frequent monitoring of ECF using BIS Measurements, is a more sensitive method than weight to monitor fluid status in patients with heart failure and may help guide diuretic therapy after hospitalisations.

Bioimpedance spectroscopy offers an objective measure of heart failure stability during a viral pandemic

The abstract addressed a concern that patients with heart failure related congestion were potentially being misclassified and diuretic therapy delayed when presenting with shortness of breath during the COVID-19 pandemic. The study assessed 56 heart failure patients during the COVID-19 pandemic. SOZO HF-Dex measurements were obtained upon clinic visitation. The paper observed patients with HF-Dex measurements of $\geq 51\%$ required higher rates of medication and diuretic changes. These patients also felt worse which may limit misclassification of congestion when shortness of breath is the main complaint.

The abstract poster concluded: The ability to quantify congestion using BIS measures, may assist in triage of patients presenting with shortness of breath, as increasingly been the case during the COVID-19 pandemic, in clinic and acute care settings.

“The value of SOZO as an objective measure in HF is becoming more and more apparent. Our current work illustrates the device in a workflow that can better enhance the risk of fluid overload,” explained Dr. Andrew Accardi, Emergency Medicine Physician at Scripps Health in San Diego, California and lead author of the poster.

“The data from these poster presentations adds to our growing body of clinical evidence for heart failure. We believe, in time, our technology can aid clinicians with both diagnosis and therapies associated with managing heart failure patients, resulting in improved outcomes,” said Richard Carreon, Managing Director and CEO of ImpediMed.

The abstracts can be viewed at <https://hfsa.org/annualscientificmeeting/registration> by registering for the HFSA. The poster will also be available on ImpediMed's website after the conclusion of the meeting.

Approved for release by the Managing Director and CEO, Mr Richard Carreon.

Contact Details

Investor relations Contact:

Mike Bassett, ImpediMed

T: +61 407 431 432

E: mbassett@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition sold in select markets globally.

For more information, visit www.impedimed.com.

About SOZO Fluid Analysis for Heart Failure

The SOZO fluid analysis for heart failure provides an objective measure of fluid overload in heart failure patients. It utilises ImpediMed's HF-Dex™ heart failure index which is a measure of extracellular fluid as a percent of total body water. HF-Dex is presented on BIS-derived reference ranges which indicate normal fluid volumes, elevated fluid volumes, and fluid overload, which is defined as HF-Dex greater than 51%. When used as part of a clinical assessment of heart failure patients, SOZO helps differentiate between fluid and tissue-related weight changes, track response to medication changes, and provides a marker for readmission when HF-Dex is higher than 51%.

For more information, visit: <https://www.impedimed.com/healthcare/heart-failure/>.

About SOZO Digital Health Platform

SOZO, the world's most advanced, noninvasive bioimpedance spectroscopy (BIS) device, delivers a precise snapshot of fluid status and tissue composition in less than 30 seconds. Using ImpediMed's BIS technology, SOZO measures 256 unique data points over a wide spectrum of frequencies from 3 kHz to 1000 kHz. Results are available immediately online for easy data access and sharing across an entire Healthcare system. The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphedema, provides fluid status for patients living with heart failure, and can be used to monitor and maintain overall health – all on a single device.

For more information, visit: <https://www.impedimed.com/products/sozo/>.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.